CompletedPhase 3NCT00486018

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Genentech, Inc.
Principal Investigator
Roman Rubio, M.D., MD
Genentech, Inc.
Intervention
Ranibizumab injection 0.3 mg(drug)
Enrollment
397 enrolled
Eligibility
18 years · All sexes
Timeline
20072009

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00486018 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials